Endologix Inc. (NASDAQ:ELGX) Institutional Ownership stands at 0


Endologix Inc. (NASDAQ:ELGX) reported its last quarter results on 11/01/2016. This Company belongs to Medical sector.

In the last trading session, The Company traded 1.68 Million shares. The Stock Market opened sessions at 6.05 and closed at 6.05. There was a stock increase by 0.5 percent.

According to Yahoo Finance, the price target for the company which analysts are aiming is 11. The 1-year price target of the company is 8.68.

Investors expected a price target of -0.1 for this quarter.  Zacks Investment Research gave Endologix Inc. (NASDAQ:ELGX) a rating of 1.89 on a scale of 1 to 5. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.

Considering the performance, Endologix Inc. (NASDAQ:ELGX)’s shares have the potential to reach a high EPS of -0.09 per share, and a low EPS of -0.25 per share in the current quarter. All of these Earnings estimates are a consensus recommendation of 10 Analysts. According to them, the median (average) EPS the company could deliver is -0.17/share. While the actual EPS the company reported in the same quarter previous year was -0.08/share.

For the quarter ending 08/02/2016, The Analyst projected that the company could deliver EPS of -0.2 while the company provided its Actual EPS of -0.2 showing a difference of 0 Percent between the Estimated and Actual EPS. Hence, the surprise factor was 0 percent.

Analysts estimated $-0.15/share for the previous Quarter, where Endologix Inc. (NASDAQ:ELGX) reported Actual EPS of $-0.11/share with the difference of 0.04 percent and a surprise of 26.7 percent.

The 10 analysts offering 12-month price forecasts for EndologixInc have a median target of 9.50, with a high estimate of 11.00 and a low estimate of 6.30. The median estimate represents a +57.02% increase from the last price of 6.05.

For the current quarter, the highest estimate analysts provided is 54 Million and the lowest is 47.9 Million. These 10 Analysts are also projecting the mean revenue estimate of 50.51 Million. The year ago sales the company reported in the same quarter is 39.23 Million.

While Looking at Sales Growth (Year/est), the company is currently showing a percentage value of -39.6 percent.

Endologix Inc. (NASDAQ:ELGX) topped its 52-week high price target of 14.5 on Jul 12, 2016. The company reached a 52-week low at 4.78 on Dec 28, 2016.

The company’s stock currently has 542.87 Million in market capitalization. The volatility rate is 7.40% percent and 7.99% percent each. Price per earning (ttm) stands at 0.

This year, the company showed a disappointed -39.6 percent of growth. The next year’s growth is calculated to be 10.8 percent. The company projects a long term annual growth estimate of 36.95 percent.

Company Profile:

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.